A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. // Cell Reports Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2666379126005550?dgcid=rss_sd_all
A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. Cell Reports Medicine. https://www.sciencedirect.com/science/article/pii/S2666379126005550?dgcid=rss_sd_all
“A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome.” Cell Reports Medicine.
@article{article99856,
title = {A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome},
journal = {Cell Reports Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2666379126005550?dgcid=rss_sd_all}
}